logo
GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim

GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim

Globe and Mail30-06-2025
DelveInsight's 'CTD-ILD Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the CTD-ILD, historical and forecasted epidemiology as well as the CTD-ILD market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of CTD-ILD, offering comprehensive insights into the CTD-ILD revenue trends, prevalence, and treatment landscape. The report delves into key CTD-ILD statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging CTD-ILD therapies. Additionally, we cover the landscape of CTD-ILD clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of CTD-ILD treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the CTD-ILD space.
The CTD-ILD market size was valued ~USD 1,498 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In 2023, the United States held the largest market share for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), contributing approximately 70% of the total market size across the 7MM. This was significantly higher compared to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
In 2023, Germany recorded the largest market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) among EU countries, reaching nearly USD 84 million, while Spain had the smallest market size at USD 38 million.
Japan's market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) was approximately USD 136 million in 2023, representing 9% of the total market across the 7MM.
Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others
Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others
The CTD-ILD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CTD-ILD pipeline products will significantly revolutionize the CTD-ILD market dynamics.
According to DelveInsight's evaluation, the total prevalent cases of Interstitial Lung Disease (ILD) in the 7MM were approximately 1,662,000 in 2023.
In 2023, the United States recorded the highest number of diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), approximately 132,000, with numbers anticipated to increase in the future.
Within Europe, the UK reported the highest number of diagnosed prevalent cases of CTD-ILD in 2023, approximately 27,000, followed by Germany with 25,000 cases. In contrast, Spain had the lowest prevalence, with around 11,000 cases.
In 2023, Japan reported approximately 68,000 diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), representing around 23% of the total cases across the 7MM.
In the US in 2023, type-specific diagnosed cases of CTD-ILD were highest for pSS-ILD (approximately 38,000), followed by SSc-ILD (around 31,000), Other CTD-ILDs (roughly 30,000), RA-ILD (about 20,000), DM-ILD/PM-ILD (close to 8,000), and SLE-ILD (nearly 5,000).
Connective Tissue Disease associated with Interstitial Lung Disease Overview
Connective Tissue Disease (CTD)-associated Interstitial Lung Disease (ILD) refers to a group of lung disorders that occur as a result of underlying connective tissue diseases. These diseases, such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and polymyositis, can cause inflammation and scarring in the lungs, leading to ILD. This condition results in impaired lung function, breathing difficulties, and decreased oxygen levels. The damage is often progressive and can lead to respiratory failure if left untreated. Early diagnosis and management are crucial to managing symptoms and slowing disease progression. Treatment typically involves immunosuppressive medications and management of the underlying CTD.
CTD-ILD Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Connective Tissue Disease associated with Interstitial Lung Disease Epidemiology Segmentation:
The CTD-ILD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Download the report to understand which factors are driving CTD-ILD epidemiology trends @ CTD-ILD Epidemiology Forecast
CTD-ILD Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CTD-ILD market or expected to get launched during the study period. The analysis covers CTD-ILD market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the CTD-ILD Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
CTD-ILD Therapies and Key Companies
Belimumab: GlaxoSmithKline
bosentan: Actelion
Tulisokibart: Prometheus Biosciences
Rituximab: Eric Matteson
Vixarelimab: Genentech, Inc.
OFEV: Boehringer Ingelheim Pharmaceuticals, Inc.
Belimumab, GSK1550188 (BENLYSTA): GlaxoSmithKline plc.
Connective Tissue Disease associated with Interstitial Lung Disease Market Drivers
Increasing Prevalence of CTD-ILD
Advances in Diagnostic Techniques
Emergence of Novel Therapies
Rising Awareness Among Healthcare Providers
Aging Population
Regulatory Approvals for Targeted Treatments
Supportive Healthcare Policies
Connective Tissue Disease associated with Interstitial Lung Disease Market Barriers
High Cost of Treatment
Limited Drug Approvals
Challenges in Early Diagnosis
Heterogeneity of CTD-ILD
Side Effects of Current Treatments
Lack of Awareness in Emerging Markets
Inconsistent Clinical Guidelines
Scope of the Connective Tissue Disease associated with Interstitial Lung Disease Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others
Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others
CTD-ILD Therapeutic Assessment: CTD-ILD current marketed and CTD-ILD emerging therapies
CTD-ILD Market Dynamics: CTD-ILD market drivers and CTD-ILD market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Table of Contents
1. CTD-ILD Market Report Introduction
2. Executive Summary for CTD-ILD
3. SWOT analysis of CTD-ILD
4. CTD-ILD Patient Share (%) Overview at a Glance
5. CTD-ILD Market Overview at a Glance
6. CTD-ILD Disease Background and Overview
7. CTD-ILD Epidemiology and Patient Population
8. Country-Specific Patient Population of CTD-ILD
9. CTD-ILD Current Treatment and Medical Practices
10. CTD-ILD Unmet Needs
11. CTD-ILD Emerging Therapies
12. CTD-ILD Market Outlook
13. Country-Wise CTD-ILD Market Analysis (2020–2034)
14. CTD-ILD Market Access and Reimbursement of Therapies
15. CTD-ILD Market Drivers
16. CTD-ILD Market Barriers
17. CTD-ILD Appendix
18. CTD-ILD Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Ikky Khan Appointed Chief Executive Officer of Absolute Medical Response
Ikky Khan Appointed Chief Executive Officer of Absolute Medical Response

Globe and Mail

time2 hours ago

  • Globe and Mail

Ikky Khan Appointed Chief Executive Officer of Absolute Medical Response

Sydney, Australia--(Newsfile Corp. - July 31, 2025) - Absolute Medical Response (AMR), one of Australia's leading providers of Non-Emergency Patient Transport, healthcare medical services, and education, proudly announces the appointment of Ikky Khan as its new Chief Executive Officer, effective immediately. Ikky Khan Appointed Chief Executive Officer of Absolute Medical Response To view an enhanced version of this graphic, please visit: Reporting to the Chairman of the Board, Mr Khan steps into the CEO role with a bold vision and a strong, people-first leadership approach. His appointment marks a new chapter in AMR's mission to deliver reliable, compassionate, and professional care to every patient, and best-in-class healthcare education to every student, every time. With more than 20 years of leadership experience across Healthcare, Telecommunications, and FMCG sectors, Mr Khan brings a proven track record of building high-performing teams and driving strategic outcomes in both startups and multibillion-dollar enterprises. He is widely known in the industry for his collaborative style, innovative thinking, and commitment to operational excellence. "AMR has a proud history and a powerful mission," said Mr Khan. "I'm honored to lead this next phase of growth as we continue to expand our services across Australia. We remain focused on delivering outstanding patient care and exceptional training for the next generation of healthcare professionals." Under Mr Khan's leadership, AMR is set to expand its national footprint, strengthen industry partnerships, and continue shaping the future of non-emergency medical transport and healthcare education in Australia. Mr Khan is also a passionate advocate for mental health in the workplace and a committed voice for fairness, respect, and inclusion across all levels of the organisation.

Jolly Results Launches Specialized Digital Marketing Services for HVAC, Plumbing, and Roofing Contractors Across the U.S.
Jolly Results Launches Specialized Digital Marketing Services for HVAC, Plumbing, and Roofing Contractors Across the U.S.

Globe and Mail

time3 hours ago

  • Globe and Mail

Jolly Results Launches Specialized Digital Marketing Services for HVAC, Plumbing, and Roofing Contractors Across the U.S.

Jolly Results, a newly launched digital marketing agency, is making waves in the home services industry with its exclusive focus on HVAC, plumbing, and roofing contractors across the United States. After more than eight years of behind-the-scenes experience working as SEO specialists for established marketing agencies, the team at Jolly Results is stepping out on its own with a promise: to deliver fast, effective, and lead-driven marketing solutions tailored to the needs of home service professionals. Built from the ground up to understand the unique challenges of local contractors, Jolly Results offers a complete digital growth package that includes professional website design, Local SEO, and Google & Local Services Ads (LSA) and has been designed to generate consistent leads and help contractors dominate their local markets. 'We're not here to offer generic websites or cookie-cutter campaigns,' a company spokesperson said. 'Everything we create is built for speed, performance, and the specific needs of HVAC techs, roofers, and plumbers who rely on leads to keep their business running.' Through a simplified four-step process: audit, launch, generate, and scale, Jolly Results brings results in record time. Websites go live within seven days, ads start generating leads within 24 to 48 hours, and Local SEO campaigns begin showing results within the first 30 to 60 days. Real contractors are already seeing the difference. In Phoenix, an HVAC company reported a 340% increase in leads and tripled their revenue within eight months. A Dallas roofing contractor generated $2.8 million in new business from storm-related Google Ads campaigns. And in Denver, a plumbing contractor now ranks #1 for high-intent local search terms like 'emergency plumber near me,' thanks to Jolly Results' Local SEO strategy. Jolly Results offers customized solutions for each trade. HVAC websites highlight emergency contact features and seasonal services. Plumbing campaigns focus on emergency repairs, water heater installations, and trust-building content. Roofing strategies are optimized around storm damage, insurance claims, and urgent roof repairs. Each campaign is carefully designed to address the real-time needs and search behaviors of homeowners in the contractor's local area. More than just another marketing agency, Jolly Results is positioning itself as a long-term partner to contractors who are serious about scaling. Its service packages are priced transparently, with websites starting at $1,497, Local SEO at $997/month, and Google/LSA Ads at $1,497/month, and include full strategy, implementation, and ongoing optimization. 'Our mission is simple,' said the company's spokesperson. 'We help home service businesses generate more leads, close more jobs, and grow their revenue faster, without the runaround.' Contractors interested in working with Jolly Results can start with a free marketing audit and consultation to assess their current online presence and get a tailored strategy for local market domination. About Jolly Results Jolly Results is a U.S.-based digital marketing agency built exclusively for HVAC, plumbing, and roofing contractors. With years of experience and deep industry specialization, Jolly Results helps home service businesses grow their lead flow, improve their visibility, and increase revenue through data-driven websites, SEO, and Google Ads campaigns. To learn more, visit For the latest updates, follow Jolly Results on social media: Facebook: LinkedIn: Instagram: YouTube: X @JollyResults Media Contact Company Name: Jolly Results Contact Person: Sarah Email: Send Email Country: United States Website:

On tariffs, Trump is the opposite of unpredictable
On tariffs, Trump is the opposite of unpredictable

Globe and Mail

time5 hours ago

  • Globe and Mail

On tariffs, Trump is the opposite of unpredictable

So much for TACO. The notion that 'Trump always chickens out' had informed much of the thinking, and negotiating tactics, of U.S. trade partners leading up to the Aug. 1 deadline imposed by President Donald Trump for reaching deals to avoid massive tariffs on their exports. But the idea that Mr. Trump ultimately backs down no longer holds much water. Contrary to suggestions that the President is fickle and unpredictable, there has been a remarkable consistency to his approach that is becoming clearer as deals are struck with major U.S. trading partners that lock in hefty tariffs on their exports that would have been considered unthinkable not long ago. Instead, the 15-per-cent baseline tariffs agreed to by Japan and the European Union have been greeted by financial markets with sighs of relief, if not indifference. That Mr. Trump has been able to so completely transform – or undermine – the rules of the global trading system in barely six months does suggest that there is more to his method than empty taunts and bravado. Rather, his determination to extract concessions from U.S. trade partners is based on the view that his country has disproportionately borne the costs of upholding the global trading system. Whether or not you agree with that view – and most credentialed economists have not – acceptance of it now appears to be everywhere taking hold. Carney's top aide joins Canada-U.S. trade talks in Washington European Commission President Ursula von der Leyen clearly demonstrated that on Sunday when she trekked to Mr. Trump's Scottish golf course for a handshake trade deal that implements 15-per-cent baseline tariffs on EU exports to the United States, and includes EU commitments to invest US$600-billion in the U.S. economy and buy US$750-billion in American energy over three years. Asked what the United States is giving up in return for those EU concessions, Ms. von der Leyen replied: 'So, the starting point was a [trade] surplus on our side and a deficit on the U.S. side. And we wanted to rebalance the trade relation, and we wanted to do it in a way that trade goes on between the two of us across the Atlantic.' In other words, the U.S. conceded nothing, and the EU was willing to accept 15-per-cent tariffs on most of its exports that, while half the level that Mr. Trump had threatened to impose without a deal by Aug. 1, will nevertheless significantly raise the prices of European wine, cheese, pharmaceuticals and other key exports in the U.S. market. Ms. von der Leyen appears to have implicitly accepted Mr. Trump's notion of reciprocity – that is, U.S. trading partners must pay a price to access the U.S. market, while opening fully their markets to U.S. goods, to offset the costs the U.S. bears for upholding the global trade system and providing the postwar security umbrella that has kept Europe safe. Keeping Mr. Trump on board with NATO and maintaining U.S. support for Ukraine were as important to the EU as avoiding a trade war and securing access to the U.S. market. Analysis: Harsh, informal, wide-ranging: How Trump's trade talks have changed In the Trump era, no longer are trade and security negotiations kept separate from one another. Defence spending is part of the calculus that determines the level at which U.S. allies get tariffed. No wonder most have undertaken to massively boost their military budgets. Mr. Trump still sees steel as a special case whose domestic production is critical to U.S. national security. But his 50-per-cent tariffs on foreign steel and aluminum are not sustainable and will eventually begin to undermine his goal of boosting U.S. manufacturing. U.S. self-sufficiency in steel and aluminum is a pipe dream and U.S. industries that rely on imported steel and aluminum, including the auto sector, cannot bear these tariffs for long. For now, however, Mr. Trump's tariffs have not stoked inflation and the U.S. stock and bond markets – after tanking on the President's 'Liberation Day' tariffs announced in April – have bounced back. Investors no longer fear tariffs the way they did. Nor does the prospect of even bigger U.S. budget deficits appear to faze them. That could all change, of course, if tariffs-induced inflation is ignited and the one-sided deals that Mr. Trump negotiates with U.S. trading partners create a political backlash in the countries that agree to higher U.S. tariffs. Wine and cheese producers remain powerful political constituencies in France, and they are very upset with Ms. von der Leyen. French Prime Minister François Bayrou's description of the EU-US deal as 'submission' heralds a potentially rough ride for her as she attempts to win EU-wide approval for the deal. A global trade war may have been postponed, but it is far from clear that one has been averted.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store